Scientists turn viruses into weapons against deadly superbugs
Scientists are advancing a promising new way to fight antibiotic-resistant infections by using viruses that specifically target and kill harmful bacteria. An international team has released the first coordinated guidelines for personalized phage therapy, offering a roadmap for safely bringing this experimental treatment into clinical practice. Early findings are encouraging, with one study reporting improvement in…
Key points
- An international team led by the German Society for Infectious Diseases published the first coordinated clinical guidelines for personalized phage therapy.
- The guidelines set over 60 recommendations on selecting, testing, making, giving and monitoring phages, and do not endorse routine use.
- A Belgian case series of 100 patients found 77 percent improved clinically and 61 percent cleared the targeted bacteria.
An international team led by the German Society for Infectious Diseases has published the first internationally coordinated clinical guidelines for personalized phage therapy, a treatment that uses selected viruses to kill harmful bacteria. The consensus statement appeared in the journal Nature Medicine.
The work involved 20 professional organizations, 18 international experts including regulatory agency representatives, and two patient advocacy organizations. Together they set more than 60 recommendations on how phages are selected, tested, manufactured, administered and monitored, plus laboratory infrastructure, quality control, treatment documentation and research priorities.
Why phages are being studied
Antibiotic resistance is making some bacterial infections harder to treat worldwide. Bacteriophages are viruses that naturally infect and destroy bacteria, and they usually target particular species or even single strains, unlike many broad-spectrum antibiotics.
That precision means specialists must first confirm a candidate virus can kill the strain causing a patient's infection. The guidelines do not recommend phage therapy as routine treatment; they call for evaluating each patient and using it only when circumstances justify it. Controlled trials have not yet shown how reliably it works, though research so far suggests properly made and given phages are generally safe.
The guideline provides physicians, pharmacists, and regulatory authorities with a common framework for safely and responsibly incorporating phage therapy into clinical practice
— PD Dr. Silvia Würstle
Early results and hospital use
In a Belgian case series of 100 people given phage treatment, 77 percent improved clinically and 61 percent had no detectable targeted bacteria in tests. The article notes such observational studies cannot show whether phages caused the improvements.
Frankfurt University Medical Center reports ten patients successfully treated through its guideline-based phage therapy program since February 2026, targeting pathogens including Pseudomonas aeruginosa and Staphylococcus aureus. Delivery may be intravenous, by inhalation, nasal spray or sterile hydrogel. The guidelines are valid from January 5, 2026, through June 29, 2030, with annual review.
